THE CENTER

Fudan University Shanghai Cancer Center

Fudan University Shanghai Cancer Center (FUSCC) is one of the budget management units under the National Health Commission. Since its establishment on March 1, 1931 as the earliest specialized cancer hospital in China, FUSCC has now developed to be a grade-A tertiary hospital engaged in the integration of clinical practice, medical education, oncologic research and cancer prevention.

Equipped with 1,304 sick beds currently, FUSCC is made up of twenty-six departments: Department of Head & Neck Surgery, Department of Breast Surgery, Department of Thoracic Surgery, Department of Gastric Surgery, Department of  Colorectal Surgery, Department of Urology, Department of Pancreatic Surgery, Department of Hepatic Surgery, Department of Neurosurgery, Department of Bone & Soft Tissue Surgery, Department of Gynecologic Oncology, Department of Medical Oncology, Radiotherapy Center, Department of TCM-WM Integrated Oncology, Department of Comprehensive Therapy, Department of Anesthesiology, Department of Interventional Therapy, Department of Pathology, Department of Pharmacy, Department of Clinical Laboratories, Department of Endoscopy, Department of Ultrasound Diagnosis, Department of Diagnostic Radiology, Department of Nuclear Medicine, Department of Cardio-Pulmonary Function, and Department of Clinical Nutriology.
By the end of 2018, FUSCC had been staffed with 2,334 medical employees, including 611 certified practitioners, 1,043 nursing attendants and 399 medical technicians. On the staff are 320 full and associate professors (63 MD and 83 MS mentors, respectively), Prof. JIANG Guoliang holding the title of Academician, American College of Radiology.

At FUSCC, oncology and pathology are formally recognized as the key academic discipline by the Ministry of Education, respectively; oncology, pathology and TCM-WM Integrated Medicine, as the national key clinical discipline, respectively; and breast oncology, radiotherapy, pathology, as the key clinical discipline under the National Health Commission. The basic and clinical research group on breast cancer is officially labeled as an innovative team by the Ministry of Education. Municipally, FUSCC is authorized to have three clinical medicine centers on oncology, radiotherapy and breast oncology, and especially to have two clinical medicine centers in priority on malignant tumor and thoracic surgery. Its pathology is also formally recognized to be a municipal key health discipline; its oncology, pathology, radiology, gynecologic oncology and thoracic oncology, to be five municipal key specialized disciplines, which are also affiliated to Shanghai Pathology Quality Control Center, Radiotherapy Quality Control Center, Cancer Chemotherapy Quality Control Center and Shanghai Anticancer Association. 

FUSCC is equipped with National Drug Clinical Trials authorized by State Food and Drug Administration, Key Laboratory on Breast Cancer in Shanghai, Shanghai Molecular Imaging Probe Engineering and Technological Research Center, Shanghai Pancreatic Cancer Institute, Fudan University Cancer Research Institute, Fudan University Pathology Research Institute, Fudan University Breast Oncology Institute, Fudan University Pancreatic Cancer Research Institute, Fudan University Colorectal Cancer Diagnosing and Treating Center, Fudan University Nasopharynx Cancer Diagnosing and Treating Center, Fudan University Prostate Cancer Diagnosing and Treating Research Center, Fudan University Thyroid Cancer Diagnosing and Treating Research Center, Fudan University Lung Cancer Prevention & Treatment Research Center, Fudan University Biomedical Imaging Research Center, and Fudan University Malignant Melanoma Prevention & Treatment Research Center. Additionally, Academician Workstation in the name of WANG Hongyang has been set up, so has Precision Oncology Center, FUSCC of Fudan University. The national projects of hiking the capacity of diagnosing and treating difficult and complicated cancers have been promoted to a great extent.  

FUSCC remains in charge of China Oncology, Oncoradiology, Journal of Radiation Oncology (in English), and Anticancer (for the populations in general). In collaboration of the third party, FUSCC has launched the English journal of Precision Cancer Medicine.   

In 2018, FUSCC received 1,447,200 outpatient and emergency visits, accommodating 84,900 inpatients with the average stay length of 5.36 days and performing 45,000 surgeries. In terms of operation efficiency, FUSCC topped its counterparts across the country. In 2017 list of the best hospitals in China, issued by Fudan University Hospital Management Institute on November 19, 2018, FUSCC was nationally ranked the 28th, topping its counterparts in specialization, and the discipline of pathology ranked the top for eight years straight and the oncology, the second in China. Furthermore, the six disciplines of thoracic surgery, nuclear medicine, urinary surgery, general surgery and ultrasonic medicine were nominated, respectively. According to the performance figures released in 2018 by Shenkang Hospital Development Center, in Shanghai FUSCC maintained the lead in treating the seven disease entities of thyroid cancer, breast cancer, pancreatic cancer, prostate cancer, ovarian cancer, esophagus cancer and colorectal cancer, having the operation efficiency top other counterparts across the country, and was ranked from the 2nd to the 5th in treating other eight disease entities. 

In 2018, a total number of 370 research papers were published (SCI; IF: 1705.58), thanks to the increased number of research projects. There were 190 research projects in progress at different levels, 74 of which were funded by the National Natural Science Foundation, with a total fund of RMB93,800,000.00. FUSCC maintained the lead for eight years straight in Shanghai-based specialized hospitals in terms of research project number, and ranked the 6th in all of the medical institutions. For this, FUSCC won the first prize of 2017 Shanghai Scientific and Technical Progress. In medical education, FUSCC enrolled 54 MS candidates, 76 MD candidates and 15 post-doctors, turning out 47 MS and 59 MD graduates, respectively, and meanwhile received 83 rotating trainees for standardization, turning out 75.

FUSCC has made great effort to promote cooperation and collaborations at home and abroad so that a growing number of patients are benefited by quality medical services. In 2018, FUSCC was actively involved with Yangtze River Delta Medical Network, expanding medical triage services and building medical consortiums, such as the medical consortium of preventing and treating cancer, medical consortium of pathological diagnosis and telemedicine consortium so that the quality medical services could be well integrated for the patients residing there. Along with the One Belt and One Road Initiative, the framework agreement was signed with Ain Shams University to establish International United Base, in the name of China Anticancer Association, for oncologic prevention and treatment, skilled pathologist training, specimen tissue bank construction and liver cancer treatment. Beyond that, FUSCC made double efforts to advance sister-hospital projects, as indicated by signing framework agreements with MD Anderson Cancer Center at Texas in USA, The Cancer Center, Singapore National Health Group, Gustave-Roussy Institute in France, Cancer Research Institute of Kanazawa University in Japan, European Institute of Oncology in Italy, DUKE Cancer Institute in USA, Peter MacCallum Cancer Centre in Australia, The Princess Margaret Cancer Centre in Canada, University of Nottingham Scientific Cancer Center in UK. At such international platforms, collaborating activities have been carried out on many aspects of oncology, including the issue of international transfers.

Thanks to the multilateral efforts, Shanghai Proton and Heavy Ion Hospital/ Proton and Heavy Ion Center of FUSCC has been in operation for four years, producing laudable achievements and accomplishments. So far, the center has received a total number of 1733, topping its counterparts worldwide in terms of admission rate. Based on the operating experiences, great efforts are to be made to ensure the clinical quality and safety, do full justice to the advantage of targeted radiotherapy, optimize the admitting and treating process, promote the therapeutic indication and increate the efficacy and cure rate.

In 2019, FUSCC will as before strive to follow the national health strategies, optimizing its medical services and assistances, improving its MDT medical model, and building itself to be a modernized and intelligential oncologic center with a great deal of international influence in the world.